Modulation of cisplatin cytotoxic activity against leiomyosarcoma cells by epigallocatechin-3-gallate

Nat Prod Res. 2018 Jun;32(11):1337-1342. doi: 10.1080/14786419.2017.1343318. Epub 2017 Jun 23.

Abstract

The aim of this study was to investigate the cytotoxic effect cisplatin in combination with epigallocatechin-3-gallate (EGCG) on leiomyosarcoma cells (LMS cells) in order to identify a less toxic but equally effective alternative. Assays for cell proliferation, colony formation efficiency, induction of apoptosis and cell cycle arrest were performed using the IC50 of cisplatin (8.6 μΜ) as a reference value and a concentration of EGCG (30 μΜ) that caused a non-significant reduction in cell proliferation. Pre-treatment of cells with EGCG for 24 h before the addition of cisplatin increased cytotoxicity up to 8.5% (p < 0.05) and the number of apoptotic cells by 40%. Epigallocatechin-3-gallate failed to alter S-phase cell cycle arrest induced by cisplatin and to modulate cisplatin effects on mitochondrial function. These results indicate that pre-treatment with EGCG could be used as an adjunctive therapy to maximise effectiveness of chemotherapy.

Keywords: Cisplatin; apoptosis; cell cycle arrest; cytotoxicity; epigallocatechin-3-gallate; mitochondria.

MeSH terms

  • Animals
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Apoptosis / drug effects
  • Catechin / administration & dosage
  • Catechin / analogs & derivatives
  • Cell Cycle / drug effects
  • Cell Cycle Checkpoints / drug effects
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cisplatin / administration & dosage
  • Cisplatin / pharmacology
  • Inhibitory Concentration 50
  • Leiomyosarcoma / drug therapy*
  • Leiomyosarcoma / pathology
  • Mitochondria / drug effects
  • Rats, Wistar

Substances

  • Catechin
  • epigallocatechin gallate
  • Cisplatin